Skip to main content

Table 2 Rates of adverse events during the study period

From: A 14-week randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of ginseng polysaccharide (Y-75)

Adverse event or safety variable Y-75 (n= 36) Placebo (n= 36)
Volunteer with at least one adverse event, n (%) 9 (25.00) 5 (13.89)
Total number of adverse events 14 5
Clinical adverse event leading to discontinuation of study drug 0 0
Serious adverse event 0 0
Probably drug-related adverse event 0 1
Most common adverse events (with incidence >5% of volunteers), n (%)
Gastrointestinal disease 3 (8.33) 2 (6.25)
Infection 3 (8.33) 1 (2.78)
Musculoskeletal and connective disease 2 (6.25) 1 (2.78)